ScholarX

The Lancet

Journal Title

  • The Lancet

ISSN

  • E 1474-547X | P 0140-6736

Publisher

  • Elsevier Science Inc.

Listed on(Coverage)

JCR 1997-2023
SJR 1999-2020;2022-2023
CiteScore 2011-2023
SCI 2010-2019
SCIE 2010-2024
CC 2016-2024
SCOPUS 2017-2024
MEDLINE 2016-2024
EMBASE 2016-2024

Active

  • Active

    based on the information

    • SCOPUS:2024-10

Country

  • ENGLAND

Aime & Scopes

  • Lancet is the world's leading independent general medical journal. The journal's coverage is international in focus and extends to all aspects of human health. The Lancet publishes the original primary research and review articles of the highest standard. The Lancet is stringently edited and peer-reviewed to ensure the scientific merit and clinical relevance of its diverse content. Drawing on an international network of advisers and contributors, The Lancet meets the needs of physicians by adding to their clinical knowledge and alerting them to current issues affecting the practice of medicine worldwide. The blend of challenging editorials, signed commentaries, original research, commissioned reviews, an international news section, and the views of readers in the letters pages make The Lancet an essential weekly read for physicians all over the world.

Homepage

Article List

21 - 31 out of 31 results.

SCIESCOPUS
Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128.9 million children, adolescents, and adultsopen access

Ezzati, M[Ezzati, Majid]; Bentham, J[Bentham, James]; Di Cesare, M[Di Cesare, Mariachiara]; Bilano, V[Bilano, Ver]; Bixby, H[Bixby, Honor]; Zhou, B[Zhou, Bin]; Stevens, GA[Stevens, Gretchen A.]; Riley, LM[Riley, Leanne M.]; Taddei, C[Taddei, Cristina]; Hajifathalian, K[Hajifathalian, Kaveh], et al.

ArticleIssue Date2017CitationLANCET, v.390, no.10113, pp.2627 - 2642PublisherELSEVIER SCIENCE INC
SCIESCOPUS
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial

Kang, YK[Kang, Yoon-Koo]; Boku, N[Boku, Narikazu]; Satoh, T[Satoh, Taroh]; Ryu, MH[Ryu, Min-Hee]; Chao, Y[Chao, Yee]; Kato, K[Kato, Ken]; Chung, HC[Chung, Hyun Cheol]; Chen, JS[Chen, Jen-Shi]; Muro, K[Muro, Kei]; Kang, WK[Kang, Won Ki], et al.

ArticleIssue Date2017CitationLANCET, v.390, no.10111, pp.2461 - 2471PublisherELSEVIER SCIENCE INC
SCIESCOPUS
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

Rittmeyer, A.[Rittmeyer, A.]; Barlesi, F.[ Barlesi, F.]; Waterkamp, D.[ Waterkamp, D.]; Park, K.[Park, K.]; Ciardiello, F.[ Ciardiello, F.]; von Pawel, J.[ von Pawel, J.]; Gadgeel, S.M.[ Gadgeel, S.M.]; Hida, T.[ Hida, T.]; Kowalski, D.M.[ Kowalski, D.M.]; Dols, M.C.[ Dols, M.C.], et al.

ArticleIssue Date2017CitationLANCET, v.389, no.10066, pp.255 - 265PublisherELSEVIER SCIENCE INC
SCIESCOPUS
Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015

Farid, TA[Farid, Talha A.]; Nejjari, C[Nejjari, Chakib]; Murray, CJL[Murray, Christopher J. L.]; Wang, HD[Wang, Haidong]; Farinha, CSES[Sa Farinha, Carla Sofia e]; Neupane, S[Neupane, Subas]; Naghavi, M[Naghavi, Mohsen]; Faro, A[Faro, Andre]; Newton, CR[Newton, Charles R.]; Allen, C[Allen, Christine], et al.

ArticleIssue Date2016CitationThe Lancet, v.388, no.10053, pp.1459 - 1544PublisherELSEVIER SCIENCE INC
SCIESCOPUS
MERS-CoV outbreak following a single patient exposure in an emergency room in South Korea: an epidemiological outbreak study

Cho, SY[Cho, Sun Young]; Kang, JM[Kang, Ji-Man]; Ha, YE[Ha, Young Eun]; Park, GE[Park, Ga Eun]; Lee, JY[Lee, Ji Yeon]; Ko, JH[Ko, Jae-Hoon]; Lee, JY[Lee, Ji Yong]; Kim, JM[Kim, Jong Min]; Kang, CI[Kang, Cheol-In]; Jo, IJ[Jo, Ik Joon], et al.

ArticleIssue Date2016CitationLANCET, v.388, no.10048, pp.994 - 1001PublisherELSEVIER SCIENCE INC
SCIESCOPUS
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

Fehrenbacher, L[Fehrenbacher, Louis]; Spira, A[Spira, Alexander]; Ballinger, M[Ballinger, Marcus]; Kowanetz, M[Kowanetz, Marcin]; Vansteenkiste, J[Vansteenkiste, Johan]; Mazieres, J[Mazieres, Julien]; Park, K[Park, Keunchil]; Smith, D[Smith, David]; Artal-Cortes, A[Artal-Cortes, Angel]; Lewanski, C[Lewanski, Conrad], et al.

ArticleIssue Date2016CitationLANCET, v.387, no.10030, pp.1837 - 1846PublisherELSEVIER SCIENCE INC
SCIESCOPUS
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

Herbst, RS[Herbst, Roy S.]; Baas, P[Baas, Paul]; Kim, DW[Kim, Dong-Wan]; Felip, E[Felip, Enriqueta]; Perez-Gracia, JL[Perez-Gracia, Jose L.]; Han, JY[Han, Ji-Youn]; Molina, J[Molina, Julian]; Kim, JH[Kim, Joo-Hang]; Arvis, CD[Arvis, Catherine Dubos]; Ahn, MJ[Ahn, Myung-Ju], et al.

ArticleIssue Date2016CitationLANCET, v.387, no.10027, pp.1540 - 1550PublisherELSEVIER SCIENCE INC
SCIESCOPUS
Global, regional, and national levels and causes of maternal mortality during 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013

Rahimi-Movaghar, V[Rahimi-Movaghar, Vafa]; Kassebaum, NJ[Kassebaum, Nicholas J.]; ur Rahman, S[ur Rahman, Sajjad]; Bertozzi-Villa, A[Bertozzi-Villa, Amelia]; Raju, M[Raju, Murugesan]; Coggeshall, MS[Coggeshall, Megan S.]; Rana, SM[Rana, Saleem M.]; Shackelford, KA[Shackelford, Katya A.]; Refaat, A[Refaat, Amany]; Steiner, C[Steiner, Caitlyn], et al.

ArticleIssue Date2014CitationLANCET, v.384, no.9947, pp.980 - 1004PublisherELSEVIER SCIENCE INC
SCIESCOPUS
Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial

Garon, EB[Garon, Edward B.]; Ciuleanu, TE[Ciuleanu, Tudor-Eliade]; Arrieta, O[Arrieta, Oscar]; Prabhash, K[Prabhash, Kumar]; Syrigos, KN[Syrigos, Konstantinos N.]; Goksel, T[Goksel, Tuncay]; Park, K[Park, Keunchil]; Gorbunova, V[Gorbunova, Vera]; Kowalyszyn, RD[Dario Kowalyszyn, Ruben]; Pikiel, J[Pikiel, Joanna], et al.

ArticleIssue Date2014CitationLANCET, v.384, no.9944, pp.665 - 673PublisherELSEVIER SCIENCE INC
SCIESCOPUS
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial

Rini, BI[Rini, Brian I.]; Escudier, B[Escudier, Bernard]; Tomczak, P[Tomczak, Piotr]; Kaprin, A[Kaprin, Andrey]; Szczylik, C[Szczylik, Cezary]; Hutson, TE[Hutson, Thomas E.]; Michaelson, MD[Michaelson, M. Dror]; Gorbunova, VA[Gorbunova, Vera A.]; Gore, ME[Gore, Martin E.]; Rusakov, IG[Rusakov, Igor G.], et al.

ArticleIssue Date2011CitationLANCET, v.378, no.9807, pp.1931 - 1939
SCIESCOPUS
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial

Pirker R.[Pirker R.]; Pereira J.R.[Pereira J.R.]; Szczesna A.[Szczesna A.]; von Pawel J.[von Pawel J.]; Krzakowski M.[Krzakowski M.]; Ramlau R.[Ramlau R.]; Vynnychenko I.[Vynnychenko I.]; Park K.[Park K.]; Yu C.-T.[Yu C.-T.]; Ganul V.[Ganul V.], et al.

ArticleIssue Date2009CitationLANCET, v.373, no.9674, pp.1525 - 1531PublisherELSEVIER SCIENCE INC
1 2
STATISTICS
Total View:
Daily View:

RSS_1.0 RSS_2.0 ATOM_1.0

CONTACT US

(03063) 25-2, SUNGKYUNKWAN-RO, JONGNO-GU, SEOUL, KOREA samsunglib@skku.edu

COPYRIGHT © 2021 SUNGKYUNKWAN UNIVERSITY ALL RIGHTS RESERVED.

Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.

BROWSE

한국어